Apremilast for the Treatment of Concomitant Subacute Cutaneous Lupus Erythematosus and Psoriasis

Skinmed. 2022 Oct 31;20(5):391-392. eCollection 2022.

Authors

Aikaterini Tsiogka¹, Maria Gerochristou², Anastasia Agrogianni², Stamatios Gregoriou², Dimitrios Rigopoulos², Georgios Kontochristopoulos²

Affiliations

¹ 1st Department of Dermatology-Venereology, Faculty of Medicine, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece; [email protected].
² 1st Department of Dermatology-Venereology, Faculty of Medicine, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.

PMID: 36314710

No abstract available

MeSH terms

Humans
Lupus Erythematosus, Cutaneous* / complications
Lupus Erythematosus, Cutaneous* / drug therapy
Psoriasis* / complications
Psoriasis* / drug therapy
Thalidomide / therapeutic use

Substances

apremilast
Thalidomide